32 completed, 5 unknown, 4 recruiting, 3 active not recruiting. 23 Phase 1, 15 Phase 2, 9 Phase 3, 4 Phase 4, 2 Early Phase 1.
Follow entacapone: new trials by email Literature Review of entacapone trials Research Report on entacapone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence Entacapone, Bevacizumab, Placebo - Glioblastoma | Phase 1 / Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 96 | 2026-10-01 | 2026-09-21 |
| Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD) 611, Matching placebo - Dermatitis, Atopic | Phase 3 | Recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 246 | 2026-09-22 | 2026-10-09 |
| Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis 611, Matching placebo - Dermatitis, Atopic | Phase 3 | Recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 180 | 2025-08-05 | 2025-11-18 |
| Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease 611, Placebo - Pulmonary Disease, Chronic Obstructive (COPD) | Phase 3 | Recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 594 | 2025-07-16 | 2025-11-18 |
| A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps 611, Placebo - Sinusitis, Nasal Polyps | Phase 3 | Active not recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 243 | 2024-11-22 | 2025-12-03 |
| Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis 611, Placebo, Topical corticosteroid - Dermatitis, Atopic, Eczema, Atopic | Phase 3 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 417 | 2024-09-23 | 2026-09-17 |
| Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611) - Dermatitis, Atopic | Phase 1 / Phase 2 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 128 | 2024-07-10 | 2026-07-01 |
| Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis 611, Matching placebo - Dermatitis, Atopic | Phase 3 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 519 | 2024-01-22 | 2026-01-15 |
| Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in the Postprandial State in Healthy Chinese Subjects Test (T) Entacapone,Levodopa and Carbidopa Tablets (II), Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II) - Healthy | Phase 1 | Unknown | The Affiliated Hospital of Qingdao University | 36 | 2023-12-20 | 2023-12-22 |
| Evaluation of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease 611 300 mg Q2W, 611 450 mg Q2W, Matching placebo - Pulmonary Disease, Chronic Obstructive | Phase 2 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 142 | 2023-12-08 | 2025-11-20 |
| Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in Healthy Chinese Subjects Test (T) Entacapone,Levodopa and Carbidopa Tablets (II), Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II) - Healthy | Phase 1 | Unknown | The Affiliated Hospital of Qingdao University | 68 | 2023-08-17 | 2023-08-04 |
| A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps 611, Placebo - Sinusitis, Nasal Polyps | Phase 2 | Unknown | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 90 | 2023-06-30 | 2024-01-12 |
| Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease Stalevo, Carbidopa and Levodopa Controlled Release Tablets - Parkinson Disease | Phase 4 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 180 | 2022-01-01 | 2023-02-16 |
| Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis 611 150mg, 611 300mg, 611 600mg - Dermatitis, Atopic | Phase 1 / Phase 2 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 24 | 2021-10-18 | 2022-12-07 |
| Entacapone Combination With Imatinib for Treatment of GIST Entacapone, Imatinib Mesylate - Gastrointestinal Stromal Tumor, Malignant | Early Phase 1 | Completed | Xiangya Hospital of Central South University | 5 | 2020-10-30 | 2023-10-18 |
| Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Placebo, 611 - Healthy | Phase 1 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 40 | 2020-09-09 | 2022-11-10 |
| [18F]F-DOPA Imaging in Patients With Autonomic Failure [18F]FDOPA, Carbidopa 200mg oral dose, Entacapone 400mg oral dose - Autonomic Failure, Pure Autonomic Failure | Phase 1 | Recruiting | Daniel Claassen | 40 | 2020-02-04 | 2026-03-16 |
| Gait Analysis in Neurological Disease Anti-Parkinson medication, Deep Brain Stimulation - Parkinson's Disease, Parkinsonian Disorders | Active not recruiting | Beth Israel Deaconess Medical Center | 120 | 2016-03-01 | 2026-07-08 | |
| Pharmacokinetic Study in Healthy Volunteers levodopa, carbidopa, ODM-104, levodopa, carbidopa, entacapone - Parkinson's Disease | Phase 1 | Completed | Orion Corporation, Orion Pharma | 15 | 2015-08-01 | 2016-01-14 |
| Effect of Entacapone on Bodyweight Loss in Obese Population Entacapone, Placebo - Obesity | Phase 1 / Phase 2 | Unknown | Kaichun Wu | 30 | 2015-01-01 | 2015-02-02 |
Showing 20 of 47. Sign in to see all of them.
Parkinson Disease (23) · Dermatitis, Atopic (6) · Multiple System Atrophy (3) · Cocaine-Related Disorders (2) · Nasal Polyps (2) · Pulmonary Disease, Chronic Obstructive (2) · Sinusitis (2) · Autonomic Nervous System Diseases (1) · Corticobasal Degeneration (1) · Dyskinesias (1) · Gait Disorders, Neurologic (1) · Gastrointestinal Stromal Tumors (1) · Glioblastoma (1) · Huntington Disease (1) · Lewy Body Disease (1)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (11) · Bial - Portela C S.A. (8) · Orion Corporation, Orion Pharma (7) · NeuroDerm Ltd. (2) · New York State Psychiatric Institute (2) · Novartis (2) · The Affiliated Hospital of Qingdao University (2) · Assistance Publique - Hôpitaux de Paris (1) · Beth Israel Deaconess Medical Center (1) · Daniel Claassen (1) · First Affiliated Hospital of Wenzhou Medical University (1) · Kaichun Wu (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · Oregon Health and Science University (1) · Rambam Health Care Campus (1)
China (14) · United States (10) · Portugal (5) · Finland (4) · Israel (4) · France (3) · Germany (3) · Italy (2) · Canada (1) · Czechia (1) · Poland (1) · Sweden (1) · Turkey (Türkiye) (1)
Adam Bisaga, M.D. (2) · Rainard Fuhr, MD (2) · Yu Cao (2) · Bin Li, MD (1) · Dag Nyholm, MD, PhD (1) · David S Goldstein, M.D. (1) · Ehud Klein (1) · Fabrizio Stocchi, MD, PhD (1) · Joaquim Ferreira, MD, PhD (1) · Jonathan C Fellers, MD (1) · Juha Rinne, Dr (1) · Kaichun Wu, MD, PhD (1)
PMID 15911704, PMID 19058133, PMID 19687359, PMID 24002370, PMID 24227635, PMID 24495468, PMID 24606242, PMID 24721800, PMID 26171276, PMID 26725544, PMID 32673517, PMID 40979212, PMID 42764990
P50DA009236 (1), UL1TR000445 (1)